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Abstract
1. Twenty.one patients with liver diseases were studied for their urinary mehylmalonic acid
excretion after a valine load by means of an improved thin layer chromatography. 2. Methyl-
malonic acid positive cases were found in four out of the ten patients with cirrhosis of the liver,
all four with cirrhosis and diabetes mellitus, and none with acute hepatitis of icteric phase. No
apparent correlation was found between the methylmalonic acid excretion and the extent of hep-
atic damage. 3. A large amount of methylmalonic acid found in the case (S. I.) with cirrhosis
of the liver and diabetes mellitus after the valine load was not corrected by cyanocobalamin but
by DBCC, suggesting an impaired transformation from cyanocobalamin to DBCC. However, the
nature of the impairment remains unknown.
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Methylmalonic acid! is excreted in increased amount in the urine of
patients with vitamin B12 deficiency 0, 2, 3, 4, 5). The coenzyme form
2
of vitamin B12 is required for the conversion of methylmalonyl-CoA to
succinyl-CoA, and the appearance of DECC in human and animal livers
has been also demonstrated (6). On the other hand, cyanocobalamin or
hydroxocobalamin is converted into DBCC in rat and human livers (7),
and dietary restriction of vitamin B. 2 results in a decrease of the hepatic
coenzyme level (8). A possibility exists, therefore, that an impaired
conversion of vitamin B. 2 into DBCC might cause the lowering of the liver
coenzyme content, hence the excretion of MMA.
Recently, UKYO (9) reported patients with liver diseases who excreted
MMA in urine after oral administration of valine which enhances MMA
excretion in vitamin B.2 deficiency (5, 10). The present study was under.
taken to know in what liver diseases MMA is excreted in urine and what
effects vitamin B12 derivatives have on the MMA excretion. The estimation
of MMA in urine was carried out by a rapid thin layer chromatographic
technique and its validity was also studied.
SUBJECTS AND METHODS
Twenty-four patients mostly of liver diseases (see Fig. 2) admitted to the
Okayama University Hospital and its affiliated hospitals have been studied. The
patients have not received parenteral administration of vitamin B12 derivatives
and their oral administration, when they had been received, was discontinued
at least [or ten days before collection of urine for MMA assay.
Urinary MMA was estimated semiquantitatively by thin layer chromato-
graphy essentially as described by BASHIR and others3 (1) except for the develop-
1. MMA: methylmalonic acid
2. DBCC: 5, 6-dimeth) lbenzimidazol~lcobamidecoenz) me
3. In our preliminar" e: periments with their solvent s> stem, a difficulty was found
in sepa-
ratipg MMA from hippuric acid, which is usually present in large c.uantities in u
rine.
This difficulty could be eliminated by use of the s) stem of DREIFUS and DUBE with
minor modification;
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ing solution which was replaced by that of DREIFUS and DUBE (12) after a slight
modification of the solvent system; the ethanol concentration was reduced to 74
per cent (v IV) in order to increase the R r value of MMA (Fig. 1). The quantita-
tion of MMA concentration on the chromatogram was done according to UKYO
and WAKISAKA (9). The recovery of added MMA (40 /-tg/l ml urine) from normal
urine was found to be 80 per cent, this value being used for correction. Since
the lower limit of determination by the present method was 10 /J.g, for urine
samples containing less than 10 t-tg MMA, an adequate amount of MMA was
added to bring MMA content to a measurable range in the final application to
the thin layer plate.
Succinate content in urine was determined by thin layer chromatography
using the two kinds of developing solution as described before for the separation
of MMA 01, 12).
Several metabolite contents in blood were estimated before and after admi-
nistration of DBCC. Those included blood sugar (3), serum NEFA (4), blood
Fig. A thin layer chromatogram showing BeG-positive spots of authentic MMA and
ether extracts from urine samples I, 2 and 4, urine from a MMA-excreting patient (Case
S. 1.); 3, internal standard (normal urine plus authentic MMA); 5, 6, 7 and 8, MMA
standards, 20, 30, 40 and 50 g, respectively (Rr: (). 22) 0: origin. Arrow indicates the
direction of development. ~:uccinic acid appears as a distinct comet-shaped spot ahead of
methylmalonic acid. In order to avoid a possible effect of the presence of other urinary
metabolites on Rr value of MMA, the identification of an equivocal spot was established
by confirming the addictive effect of authentic MMA or by the response of the spot size
to vitamin BJ2 administrations.
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Fig. 2 Urinary MMA excretion in liver:diseases after the valine load
Each circle represents one patient. The patients with acute hepatitis had jaundice
at the time of thi3 examination.
• : severe cases of cirrhosis of the liver, 0: Case S. 1. Ohters included 2 dia-
betes mellitus, 2 chronic hepatitis, 1 Budd-Chiari syndrome, 1 primary hepatoma
and 1 healthy adult.
pyruvate (15), lactate (16), citrate (17), and a-ketoglutarate (18). DBCC used for
injection was the product of Yamanouchi Pharmaceutical. Co., Ltd (Tokyo).
MMA was obtained from Sigma Chemical Company.
RESULTS
Urinary excretions of MMA after the valine load in liver diseases are
shown in Fig. 2. No MMA was detected in the urine of any of the three
patients with acute hapatitis. Among fourteen patients with cirrhosis of the
liver, eighth showed positive MMA in urine. Severity of the disease as
evidenced by jaundice, ascites, hyperammonemia, etc. was not always
correlated with the positive result, while all four patients of cirrhosis
were complicated with diabetes mellitus excreted MMA in various degrees.
Other seven subjects including two diabetes with neuralgia, two chronic
hepatitis, one Budd-Chiari syndrome, one primary hepatoma and one
healthy adult developed negative result.
Further examinations in relation to vitamin B12 treatment were per-
formed on one patient of liver cirrhosis with diabetes mellitus whose urinary
MMA excretion was 42 mg in twenty-four hours after the valine load.
Case Presentation
S. 1., a 58.year-old female, was admitted to the Okayama University
Hospital on May 19, 1969. She had gradually noticed malaise and anorexia
sine.,:: three years before admission. Diagnoses of liver cirrhosis and diabetes
mellitus were made and she had been treated with medicines untill the time
3
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[Cj~~~J"I1MJill bBCC!3.5~9 3.5 ~jJ
105
of h03pitalization. Ten day.; before admission she develo;>ed an intermittent
fever, expectoration and tender swelling of the left arm (phlegmon).
Physical findings revealed distended abdomen and enlarged splenic
dullness, although liver and spleen were not palpated. Urinary sugar
was positive while negative for ketone bodies. The hemoglobin concent-
ration was 10.5 gj 100 ml; erythrocytes, 3, 880, 000 j mm3 ; the color index,
0.8; leucocytes, 14,700jmm3, with 85?6 neutrophils including 36 % band
form; and platelets, 135,000jmm3• The serum bilirubin was 0.85 mg
direct and 1.49 mg totalj 100 ml; serum cholesterol, 70mgj 100 ml; serum
iron, 92r j 100 ml; fasting blood sugar, 127 mgjI 00 ml; SGOT and SGPT,
27 and 22 Karmen units, respectively; alkaline phosphatase, 3.3 Bessey
units; the cobalt chloride reaction, Ro ; CCF, three positive; TTT, 5
Maclagan units; ZnTT, 12 Kunkel units; and the total serum protein,
5. 2gj 100 m1; with 36.5?6 r-globulin. The bromsulphthalein retention
was 24.8 96 after 45 minutes. The other laboratory findings remained
within normal limits.
One month's admission brought her marked recovery in general con·
dition. OnJune 28 MMA excretion after the valine load was found to be
42 mg per day and its excretion rose to 105 mg even after intramuscular
administration of a daily dose of O. 5 r~g of cyanocobalamin for seven days.
However, when the same dose of DBCC was given in the same way, MMA
excretion fell to 39 mg per day and disappeared by 50 r!g of DBCC.
On September 18, MMA appeared in urine again inspite of daily oral
administration of 1500 r:g cyanocobalamin and came to undetectable by
repeated treatment of lOOr:g of DBCC (Fig. 3). When MMA excretion
MMAinUrine
mglday
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Fig. 3 Urinary MMA excretion during the course of vitamin BI2 treatment
Each hatched bar and the number above it indicate the amount of MMA in
24-hour urine after the valine load. Each arrow represents a single daily injection
of vitamin BI2 and the total dose is given in the rectangle above.
CN-BI2: cyanocobalamin
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decreased to nearly zero after 50 jag of DBCC injection, it was noted that
succinate excretion in urine rose to a large quantity, while urinary valine
excretion barely exceeded the normal level.
The effect of DBCC treatment on some blood metabolites in the
valine load was studied and summarized in Fig. 4A and 4B. A sharp transi.
ent increase in pyruvate, but not in lactate and glucose following the
valine load was found after DBCC treatment. The elevated blood citrate
and NEFA decreased to nearly normal levels, while a.ketoglutarate level
was high and unchanged.
Throughout the four months of her illness, she maintained erythrocyte
counts of 380-400 X104/mm3, with hemoglobin levels of 10.5-llgjlOO
m!. The bone marrow was not examined.
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Fig. 4A and B The effect of cobamide coenzyme on blood metabolites in
the valine load
0-0, before DBCC administration; 0· .. 0, after DBCC administration
e-·-·., normal male control without DBCC administration
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DISCUSSION
UCHINO (8) reported that conversion from cyanocobalamin or hydro-
xocobalamin to coenzyme form of vitamin Bj2 occurred in normal rat liver
and CC14 injuries resulted in a significant decrease in DBCC content in
liver, indicating the disturbance of DBCC formation in some conditions
with liver injury. A possibility exists that deficiency of cobamide coenzyme
in tissues and urinary MMA excretion might occur in severe liver damage.
This was extensively studied by U KYO and WAKISAKA (9) in liver diseases
and CC14-injured rats, and they suggested the presence of an impaired
conversion of vitamin Bj2 to DBCC in liver injuries in man as well as in
experimental animals. The present clinical study confirmed their results
by means of the improved thin layer chromatographic technique, which
could eliminate overlapping of MMA and hippuric acids spots.
Clinical observations seen in Fig. 2 indicate that urinary MMA excre-
tion after the valine load occurs not in the patients with acute hepatitis of
icteric phase, but in those with more chronic liver damage. It is of interest
that all four cases ccomplicated with diabetes responded positively for
urinary MMA and in one of them (S. I,) the excraction of large amounts
ofMMA.
We could not find out a clear clinical difference between MMA posi-
tive and negative cases, on the point that MMA negative cases were
noticed even among the patients with severe cirrhosis. In other words,
there is no apparent correlation between the MMA excretion and the
extent of hepatic damage. In the case of S. 1. MMA excretion in urine
was not corrected by cyanocobalamin but by DBCC administration. This
is far from the evidence that not only the spot separated by the present
MMA with thin layer chromatography is identified as MMA, but also the
method excretion in this patient is due to the impaired transformation
from cyanocobalamin to DBCC. However, the nature of this impairment
has not been clarified yet.
Recently MUDD, S. H. and his associates (9) reported an infant with
abnormalities of both sulfur amino acids and methylmalonic acid metabo-
lism and concluded as a failure to transform vitamin Bj2 into coenzymati-
cally active derivatives. The urine of this patient consistently contained
abnormally elevated homocystine, cystathionine, the mixed disulfide of
homocysteine and cystein, and MMA. Methionine was not detected in
urine.
The decrease in MMA excretion seen in the present case following
DBCC treatment was associated with increased excretion of succinate,
6
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enhanced formation of pyruvate after the valine load, and decreased
blood citrate at zero time and NEFA levels. An increased pyruvate forma-
tion from amino acids in cirrhosis of the liver was reported by KIMURA (20).
The elevated blood citrate and NEFA levels are known to be associated
with gluconeo.senic or ketogenic condition (21). A metabolic keto.acidosis
was also observed in the methylmalonic aciduria, probably an inborn
enzymatic defect in the conversion of methylmalonyl-CoA to succinyl-CoA
(22, 23).
Accordingly, these evidences support the idea that the present case
was improved by DBCC treatment not only in terms of MMA excretion
but also in terms of latent ketotic and hindered gluconeogenic conditions.
SUMMARY
1. Twenty.one patients with liver diseases were studied for their
urinary mehylmalonic acid excretion after a valine load by means of an
improved thin layer chromatography.
2. Methylmalonic acid positive cases were found in four out of the
ten patients with cirrhosis of the liver, all four with cirrhosis and diabetes
mellitus, and none with acute hepatitis of icteric phase. No apparent
correlation was found between the methylmalonic acid excretion and the
extent of hepatic damage.
3. A large amount of methylmalonic acid found in the case (S. 1.)
with cirrhosis of the liver and diabetes mellitus after the valine load was
not corrected by cyanocobalamin but by DBCC, suggesting an impaired
transformation from cyanocobalamin to DBCC. However, the nature of
the impairment remains unknown.
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